FY2025 Earnings Estimate for Bruker Issued By Zacks Research

Bruker Co. (NASDAQ:BRKR - Free Report) - Zacks Research raised their FY2025 earnings per share (EPS) estimates for shares of Bruker in a research note issued to investors on Tuesday, March 11th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings per share of $2.68 for the year, up from their previous estimate of $2.67. The consensus estimate for Bruker's current full-year earnings is $2.69 per share.

Several other equities analysts also recently commented on the company. Barclays cut their target price on Bruker from $69.00 to $65.00 and set an "overweight" rating for the company in a research report on Monday, February 10th. Guggenheim restated a "buy" rating on shares of Bruker in a research report on Monday, February 24th. UBS Group initiated coverage on Bruker in a research report on Tuesday, December 10th. They set a "neutral" rating and a $66.00 target price for the company. Bank of America raised their target price on Bruker from $78.00 to $80.00 and gave the stock a "buy" rating in a research report on Friday, December 13th. Finally, The Goldman Sachs Group upgraded Bruker from a "sell" rating to a "neutral" rating and set a $60.00 price objective for the company in a research report on Thursday, December 5th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $70.50.

Remove Ads

Bruker Stock Performance

Shares of NASDAQ:BRKR traded up $0.20 during trading on Friday, hitting $47.14. 1,551,385 shares of the stock were exchanged, compared to its average volume of 1,284,629. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. The company has a market capitalization of $7.15 billion, a price-to-earnings ratio of 62.03, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. Bruker has a 1-year low of $44.11 and a 1-year high of $94.86. The company's fifty day simple moving average is $53.38 and its 200-day simple moving average is $58.22.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%.

Bruker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Monday, March 17th will be paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.42%. The ex-dividend date is Monday, March 17th. Bruker's dividend payout ratio (DPR) is presently 26.32%.

Hedge Funds Weigh In On Bruker

Several large investors have recently bought and sold shares of BRKR. FMR LLC lifted its holdings in Bruker by 21.4% in the third quarter. FMR LLC now owns 14,306,122 shares of the medical research company's stock valued at $987,981,000 after buying an additional 2,521,904 shares during the period. London Co. of Virginia lifted its holdings in Bruker by 78.4% in the fourth quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company's stock valued at $245,820,000 after buying an additional 1,843,294 shares during the period. Sculptor Capital LP lifted its holdings in Bruker by 484.1% in the fourth quarter. Sculptor Capital LP now owns 1,714,015 shares of the medical research company's stock valued at $100,476,000 after buying an additional 1,420,569 shares during the period. FIL Ltd lifted its holdings in Bruker by 262.3% in the fourth quarter. FIL Ltd now owns 1,961,416 shares of the medical research company's stock valued at $114,978,000 after buying an additional 1,420,102 shares during the period. Finally, Steadfast Capital Management LP acquired a new position in Bruker in the fourth quarter valued at approximately $63,997,000. 79.52% of the stock is currently owned by institutional investors and hedge funds.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.